IVVD | Invivyd, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	1.0800 - 1.1600
52 Week Range	0.8120 - 5.20
Beta	0.64
Implied Volatility	441.19%
IV Rank	96.47%
Day's Volume	238,233
Average Volume	636,564
Shares Outstanding	119,443,000
Market Cap	136,165,020
Sector	Healthcare
Industry	Biotechnology
IPO Date	2021-08-06

Valuation
Profitability
Growth
Health
P/E Ratio	-0.63
Forward P/E Ratio	N/A
EPS	-1.80
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	94
Country	USA
Website	IVVD

Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease. Adagio Therapeutics, Inc. has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was incorporated in 2020 and is based in Waltham, Massachusetts.

IVVD's peers: ABEO, ACIU, APVO, PMCB, EXAI, RXRX, AVIR, UBX, ICVX, RGNX, ANEB, BDTX, GBIO, KRON, ERAS, CCCC, EWTX, PASG, MGTA, TCON

*Chart delayed

Analyzing fundamentals for IVVD we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is very weak. For more detailed analysis please see IVVD Fundamentals page.

Watching at IVVD technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on IVVD Technicals page.